Retatrutide LY-3437943 lyophilized peptide vial — OMNIPOTENT ≥99% HPLC research reference compound for weight loss research in India

Retatrutide for Weight Loss: What Published Research Shows (India 2026 Reference)

Retatrutide (LY-3437943) is the single most-discussed research peptide of 2026. If you've been reading about "the next generation after Ozempic and Mounjaro", that is almost certainly Retatrutide — a synthetic 39-residue peptide that simultaneously engages three receptors (GIP, GLP-1, and glucagon) and has produced the largest body-weight reductions ever published in a Phase 2 weight-loss trial.

This guide is a research-literature reference for India scientists, biohackers, and laboratory buyers who want to understand what the published data actually says — not a therapeutic recommendation. Retatrutide is an investigational compound; it is not approved by CDSCO, the US FDA, or any other regulator for any human or veterinary use. The information below summarises the published trial literature and is supplied for in-vitro laboratory research context only.

TL;DR — what the published research says

  • Compound: Retatrutide / LY-3437943, a synthetic 39-aa fatty-acid-modified peptide.
  • Class: Triple agonist of GIP, GLP-1, and glucagon receptors — the first widely studied molecule in this class.
  • Published Phase 2 trial (Jastreboff et al., NEJM 2023): 48-week mean body-weight reduction of approximately 24% at the highest dose arm — the largest reduction ever reported in a published GLP-1-class trial.
  • Mechanism context: Adding glucagon-receptor agonism on top of GIP+GLP-1 is hypothesised in the literature to drive additional energy expenditure, not just appetite reduction.
  • India research-grade material: OMNIPOTENT supplies HPLC ≥99% lyophilised Retatrutide in 10 mg and 20 mg vials from ₹9,499.

What is Retatrutide (LY-3437943)?

Retatrutide is a synthetic 39-amino-acid peptide first disclosed in Eli Lilly research literature under the development code LY-3437943. Structurally, it is a fatty-acid-modified peptide engineered for once-weekly pharmacokinetics in the published trial protocols. CAS number 2381089-83-2; molecular weight approximately 4,731 Da.

What distinguishes Retatrutide from other peptides in the "GLP-1 class" is that it acts at three receptors at once:

  1. GIP receptor (GIPR) — same target as Tirzepatide; involved in incretin physiology
  2. GLP-1 receptor (GLP-1R) — the original target of Semaglutide, Liraglutide, and the entire first generation
  3. Glucagon receptor — a target NOT engaged by Semaglutide or Tirzepatide; activation in research literature is associated with increased energy expenditure and hepatic glucose mobilisation

This is why Retatrutide is described in the literature as the first triple agonist in the GLP-1-class — it adds a third mechanism (glucagon) on top of what Tirzepatide already does.

Published Phase 2 trial data — what was actually observed

The pivotal published reference is the Phase 2 trial reported by Jastreboff and colleagues in the New England Journal of Medicine (2023). The trial enrolled 338 adults with obesity and randomised them to placebo or one of four Retatrutide dose arms (1, 4, 8, or 12 mg) administered subcutaneously once weekly for 48 weeks.

The headline result: at week 48, mean body-weight reduction from baseline reached approximately 24.2% in the 12 mg dose arm, compared with about 2.1% in the placebo arm. That magnitude is unprecedented in the published GLP-1-class trial literature — prior best-in-class results (Semaglutide STEP trials at 14.9% mean reduction; Tirzepatide SURMOUNT trials at 20.9%) are both meaningfully lower.

Subsequent reports have published 24-week extension data, lipid-profile observations, and waist-circumference reductions consistent with the headline weight-loss numbers. The Phase 3 programme (TRIUMPH) is ongoing as of mid-2026 with multiple obesity, type-2 diabetes, and metabolic-associated steatohepatitis (MASH) read-outs expected by 2027.

Why three receptors matter (in the published literature)

Single-receptor GLP-1 agonists (Semaglutide, Liraglutide) act primarily by slowing gastric emptying and reducing appetite. Dual agonists (Tirzepatide = GIP + GLP-1) add incretin-driven insulin sensitisation. Retatrutide's additional glucagon-receptor agonism brings a mechanism that the prior generations do not touch: increased energy expenditure and hepatic lipid mobilisation.

The published research hypothesis is that while GLP-1 reduces caloric intake, glucagon increases caloric output — and the combination explains why Retatrutide produces larger total body-weight reductions than either single or dual agonists at comparable doses in the published trials. Whether this hypothesis fully accounts for the observed numbers is an active area of preclinical and clinical research in 2025-2026.

Retatrutide vs Tirzepatide vs Semaglutide — research-class summary

Compound Receptor targets Class Published mean body-weight reduction (top dose, ~48-72 wk)
Semaglutide GLP-1R Single agonist ~14.9% (STEP 1)
Tirzepatide GIPR + GLP-1R Dual agonist ~20.9% (SURMOUNT-1, 15 mg)
Retatrutide GIPR + GLP-1R + Glucagon-R Triple agonist ~24.2% (Phase 2, 12 mg)

Note: head-to-head Phase 3 trial data between these compounds at matched doses and durations is not yet published. The numbers above are from independent trials with different designs.

What India research laboratories are studying in 2026

Among India-based research groups, Retatrutide is most often the subject of:

  • In-vitro receptor-binding assays — confirming the published affinity and selectivity profile against recombinant GIPR, GLP-1R, and glucagon-receptor cell lines
  • Comparative analytical method development — HPLC and mass-spectrometry protocols benchmarking Retatrutide against Tirzepatide and Semaglutide reference standards
  • Stability and formulation studies — because Retatrutide has a longer fatty-acid-modified backbone than Semaglutide, the published degradation kinetics differ; multiple India labs are characterising stability profiles under Indian-climate temperature stress
  • Combinatorial peptide research — some groups are studying Retatrutide alongside other metabolic-pathway reference compounds such as Tesamorelin

Reference dose ranges in published research protocols

For research-literature context only — these are dose ranges referenced in the published Phase 1 and Phase 2 trial protocols, not a therapeutic recommendation and not applicable to any individual outside of a registered clinical trial:

  • Phase 1 dose-escalation: 0.5 – 12 mg once weekly subcutaneously, with dose-titration protocols starting at lower doses
  • Phase 2 Jastreboff trial: 1, 4, 8, 12 mg dose arms (titrated to target)
  • Phase 3 TRIUMPH programme: doses include 4, 8, and 12 mg

Researchers in laboratory settings designing in-vitro studies typically use molar concentrations derived from the published Kd/EC50 values for each receptor, which is a separate calculation from the in-vivo dose figures above.

Lyophilised vials vs pre-mixed pens — why researchers choose lyophilised in India

Retatrutide is sold in India in two formats: lyophilised (freeze-dried) sealed vials and pre-mixed pens or cartridges. For genuine laboratory research, lyophilised vials are almost always the correct choice:

  • Stability: Lyophilised Retatrutide is stable for 24+ months at 2–8 °C in sealed vials. Pre-mixed pen solutions degrade meaningfully faster, especially in cross-India shipping with summer ambient temperatures of 35–45 °C.
  • HPLC verification: The lyophilised lot can be HPLC-tested and the chromatogram traced back to the same powder you receive. Pre-mixed solutions can be tested too, but the result reflects the solution state at the moment of testing, not what you receive after transit.
  • Concentration flexibility: Researchers reconstitute lyophilised material to whatever concentration their protocol requires. Pre-mixed pens lock you into the vendor's dilution and titration steps.
  • Cost-per-mg efficiency: Lyophilised vials almost always cost less per milligram than equivalent pen formats in the India market.

Retatrutide price in India — 2026 benchmarks

Pricing varies enormously across India vendors. Here are honest 2026 benchmarks for genuine research-grade material (lyophilised, HPLC ≥99%, batch COA):

  • Fair INR range, 10 mg vial: ₹8,500 – ₹15,000
  • Fair INR range, 20 mg vial: ₹14,000 – ₹22,000
  • Fair INR range, pre-mixed pens (60 mg): ₹20,000 – ₹40,000+ (stability concerns above)
  • OMNIPOTENT 10 mg: ₹9,499 | 20 mg: ₹16,999

Any 10 mg listing below ₹7,000 in 2026 is a strong red flag. Authentic ≥99% HPLC Retatrutide has a substantial raw-material floor; vendors selling well below that are typically either reselling unverified material, mis-stating the mass, or both.

Reconstitution and storage in Indian climate

  • Pre-reconstitution: Store the sealed lyophilised vial at 2–8 °C, protected from light. With Indian summer ambient temperatures, transfer to refrigeration the moment the package arrives.
  • Reconstitution diluent: Bacteriostatic Water (0.9% benzyl alcohol). Bundled BAC-water variants are available with the peptide at checkout.
  • Volume calculation example: 10 mg vial + 2 ml BAC water = 5 mg/ml; with a U-100 insulin syringe, 1 unit = 0.05 mg = 50 µg.
  • Post-reconstitution: Refrigerated (2–8 °C), protected from light, used within the documented stability window for the peptide.

Full reconstitution protocol in our dedicated peptide reconstitution lab guide.

Where to source Retatrutide in India — vendor checklist

Use this six-point checklist when comparing vendors:

  1. Stated HPLC ≥99% purity per lot
  2. Batch-specific Certificate of Analysis available on request
  3. Lyophilised in sealed vial (not pre-mixed)
  4. Mass-spectrometry confirmation on COA
  5. Dispatch from within India in INR, GST-compliant invoicing
  6. Compliant research-use-only language; no therapeutic claims

OMNIPOTENT Retatrutide meets all six criteria. See also our full Weight Loss & Metabolic Peptides — India collection.

FAQ

What is the most cited Retatrutide paper for weight loss?
Jastreboff et al., "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial," New England Journal of Medicine, 2023 (DOI 10.1056/NEJMoa2301972). This is the published reference for the ~24% weight reduction figure.

Is Retatrutide approved for sale in India?
No. Retatrutide is investigational. It may be sold and purchased in India strictly as a chemical reference standard for in-vitro laboratory research, subject to standard disclaimers. See our India peptide regulatory guide.

How does Retatrutide compare to Tirzepatide in published research?
Retatrutide adds glucagon-receptor agonism on top of Tirzepatide's GIP+GLP-1. In independent published trials, top-dose Retatrutide produced ~24% mean weight reduction vs ~21% for Tirzepatide — different trials, different durations, but a consistent direction in the data.

What is LY-3437943?
LY-3437943 is the Eli Lilly development code for the same molecule called Retatrutide.

Will Retatrutide replace Semaglutide and Tirzepatide?
Too early to say from the published literature. Phase 3 read-outs are expected by 2027. Most clinicians will likely have all three in the toolbox post-approval, choosing based on patient factors.

What is the price of Retatrutide in India today?
Genuine research-grade 10 mg vials run ₹8,500 – ₹15,000. OMNIPOTENT lists 10 mg at ₹9,499, 20 mg at ₹16,999.

Related research peptides and articles

Disclaimer: This article is provided for informational and research-literature context purposes only. Retatrutide (LY-3437943) is an investigational compound that is not approved by CDSCO, FSSAI, the US FDA, the EMA, or any other regulatory body for any human or veterinary use. References to published clinical trial data are research observations, not therapeutic recommendations. Material sold by OMNIPOTENT is supplied strictly as a chemical reference standard for in-vitro laboratory research and analytical method development. By placing an order, the purchaser affirms compliance with the Drugs and Cosmetics Act 1940, the Food Safety and Standards Act 2006, the Drugs and Magic Remedies (Objectionable Advertisements) Act 1954, and any applicable state/local regulations. The purchaser further affirms they are 18+ and acquiring the material solely for bona-fide in-vitro research — not for consumption, injection, application, or any in-vivo use.

Back to blog